Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis

Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic... Downloaded from http://journals.lww.com/pain by BhDMf5ePHKbH4TTImqenVJ2toCr/9wZZjwPUWvYES9lBjFbu9i0DAnSw4JagSjiU on 10/30/2020 PAIN 155 (2014) 2461–2470 www.elsevier.com/locate/pain Comprehensive review Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis a,⇑ b b a c Marta Seretny , Gillian L. Currie , Emily S. Sena , Sabrina Ramnarine , Robin Grant , b c a Malcolm R. MacLeod , Leslie A. Colvin , Marie Fallon Cancer Research UK, University of Edinburgh, Edinburgh, Scotland, UK Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, Scotland, UK Western General Hospital, University of Edinburgh, Edinburgh, Scotland, UK Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. article i nfo abstract Article history: Chemotherapy-induced peripheral neuropathy (CIPN) is a disabling pain condition resulting from chemo- Received 19 August 2014 therapy for cancer. Severe acute CIPN may require chemotherapy dose reduction or cessation. There is no Received in revised form 12 September 2014 effective CIPN prevention strategy; treatment of established chronic CIPN is limited, and the prevalence Accepted 16 September 2014 of CIPN is not known. Here we used a systematic review to identify studies reporting the prevalence of CIPN. We searched Embase, Medline, CAB Abstracts, CINAHL, PubMed http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Pain Wolters Kluwer Health

Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis

Loading next page...
 
/lp/wolters-kluwer-health/incidence-prevalence-and-predictors-of-chemotherapy-induced-peripheral-i06cGK3PyS

References (79)

Publisher
Wolters Kluwer Health
Copyright
© 2014 International Association for the Study of Pain
ISSN
0304-3959
eISSN
1872-6623
DOI
10.1016/j.pain.2014.09.020
Publisher site
See Article on Publisher Site

Abstract

Downloaded from http://journals.lww.com/pain by BhDMf5ePHKbH4TTImqenVJ2toCr/9wZZjwPUWvYES9lBjFbu9i0DAnSw4JagSjiU on 10/30/2020 PAIN 155 (2014) 2461–2470 www.elsevier.com/locate/pain Comprehensive review Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis a,⇑ b b a c Marta Seretny , Gillian L. Currie , Emily S. Sena , Sabrina Ramnarine , Robin Grant , b c a Malcolm R. MacLeod , Leslie A. Colvin , Marie Fallon Cancer Research UK, University of Edinburgh, Edinburgh, Scotland, UK Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, Scotland, UK Western General Hospital, University of Edinburgh, Edinburgh, Scotland, UK Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. article i nfo abstract Article history: Chemotherapy-induced peripheral neuropathy (CIPN) is a disabling pain condition resulting from chemo- Received 19 August 2014 therapy for cancer. Severe acute CIPN may require chemotherapy dose reduction or cessation. There is no Received in revised form 12 September 2014 effective CIPN prevention strategy; treatment of established chronic CIPN is limited, and the prevalence Accepted 16 September 2014 of CIPN is not known. Here we used a systematic review to identify studies reporting the prevalence of CIPN. We searched Embase, Medline, CAB Abstracts, CINAHL, PubMed

Journal

PainWolters Kluwer Health

Published: Dec 1, 2014

Keywords: Prevalence,Risk factors,Systematic review,Meta-analysis

There are no references for this article.